As of 3:58pm ET
| -0.0169 / -1.84%|
The 3 analysts offering 12-month price forecasts for BioLine RX Ltd have a median target of 3.00, with a high estimate of 7.00 and a low estimate of 1.00. The median estimate represents a +233.29% increase from the last price of 0.90.
The current consensus among 2 polled investment analysts is to Buy stock in BioLine RX Ltd. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.